Supplementary file 1_Efficacy and safety of PD-1 inhibitors plus chemotherapy for advanced unresectable gastroesophageal cancer: a systematic review and meta-analysis of phase III randomized controlled trials.docx

The overall risk of included RCTs was low. Results found immunotherapy combined with chemotherapy improved patients’ prognosis more than single-agent chemotherapy, with corresponding increased but manageable adverse effects. Subgroup analyses by drug type further revealed that sintilimab in combination with chemotherapy exhibited more efficacy than other PD-1 inhibitor-based regimens.

The survival benefit in the immunotherapy combined with chemotherapy group compared to chemotherapy alone was seen in both PD-L1 CPS positive and TPS positive. The evidence strength was moderate.</p>Conclusion<p>Findings from this comprehensive study confirm that immunotherapy combined with chemotherapy is more efficacious than traditional chemotherapy in the first-line treatment of patients with advanced unresectable GEC.

Sintilimab combined with chemotherapy demonstrated favorable efficacy and safety profiles compared with other PD-1 therapies in terms of OS and PFS benefit without increasing TRAE base on indirect comparisons. The moderate evidence indicated PD-1 combined with chemotherapy may be a viable option for advanced unresectable GEC.</p>Systematic review registration<p>crd.york.ac.uk/PROSPERO/, identifier CRD42022325401.</p>